Genetic polymorphisms in age-related macular degeneration
AssigneeGenentech, Inc.
InventorsRobert Graham, Timothy W. Behrens, Tsontcho Ianchulev, Howard Shapiro
Life of this patent
Estimating the term…
Abstract
Methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.
Claims12
A method of predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody, comprising screening a sample isolated from said patient for a genomic polymorphism in the complement factor H gene (CFH) Y402H allele corresponding to rs1061170, wherein the patient has an increased likelihood of benefiting from said treatment if the corresponding genotype comprises CC or CT.
2-3. (canceled)
10-11. (canceled)
A kit for predicting whether a wet AMD patient has an increased likelihood of benefiting from treatment with ranibizumab comprising a first oligonucleotide and a second oligonucleotides specific for a CIT polymorphism in the CFH Y402H allele corresponding to rs1061170.
14-21. (canceled)
Dependencies are inferred from the claim text.